Journal
PHARMACOLOGY RESEARCH & PERSPECTIVES
Volume 8, Issue 2, Pages -Publisher
JOHN WILEY & SONS LTD
DOI: 10.1002/prp2.586
Keywords
PARP-1; PARP-1 inhibitors; poly(ADP-ribose); prostate cancer cells
Categories
Funding
- National Institutes of Health [R03 (CA212566)]
- Department of Defense grant [PC160049]
Ask authors/readers for more resources
The prognosis for metastatic castration-resistant prostate cancer is unfavorable, and although Poly(ADP)-ribose polymerase-1 (PARP-1) inhibitors have shown efficacy in the treatment of androgen-receptor dependent malignancies, the limited number of options present obstacles for patients that are not responsive to these treatments. Here we utilize an integrated screening strategy that combines cellular screening assays, informatics, in silico computational approaches, and dose-response testing for reducing a compound library of confirmed PARP-1 inhibitors. Six hundred and sixty-four validated PARP-1 inhibitors were reduced to 9 small molecules with favorable physicochemical/ADME properties, unique chemical fingerprints, high dissimilarity to existing drugs, few off-target effects, and dose-responsivity in the 1 mu mol/L - 20 mu mol/L range. The top 9 unique molecules identified by our integrated screening strategy will be selected for further preclinical development including cytotoxicity testing, effects on mitosis, structure-activity relationship, physicochemical/ADME studies, and in vivo testing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available